The study of the impact of changes in surface antigens on eosinophils after treatment in patients with asthma

The study of the impact of changes in surface antigens on eosinophils after treatment in patients with asthma - The study of the surface antigens on eosinophils and asthma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052207

Enrollment

Registered

2023-11-01

Start date

2023-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with asthma and asthma suspicion

Interventions

asthma controllers

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with asthma and asthma suspicion

Exclusion criteria

Exclusion criteria: 1) current and ex-heavy smokers (>10pack-year) 2) Immunosuppressive patients with active cancer and HIV infections 3) History of patients with lung resections 4) During severe or fatal asthma exacerbations 5) Other chronic respiratory diseases

Design outcomes

Primary

Measure	Time frame
The low CD62- and CD34-positive eosinophils at pre-treatment and early improvement of CD62- and CD34-positive eosinophils after treatment are estimable biomarkers of clinical remission of asthma.	—

Countries

Japan

Contacts

Public ContactTomoataka Kawayama

Department of Medicine, Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology

kawayama_tomotaka@kurume-u.ac.jp0942317560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026